

AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application:

List of Claims:

Claim 1 (Currently Amended): A method of screening for compounds which inhibit proliferation of cells selected from the group consisting of vascular cells and neoplasia cells, the method comprising:

(a) selecting a assessing the ability of the putative compound which is found to inhibit induction of Egr-1, decrease expression of Egr-1 or decrease the nuclear accumulation or activity of the Egr-1 gene product; and

(b) assessing the ability of the putative compound to inhibit proliferation of cells selected from the group consisting of vascular cells and neoplasia cells[.] ; and

(c) selecting a putative compound that has been found to inhibit induction of Egr-1, decrease expression of Egr-1 or decrease the nuclear accumulation or activity of the Egr-1 gene product and inhibit proliferation of cells selected from the group consisting of vascular cells and neoplasia cells.

Claim 2 (Previously Presented): The method of claim 1, wherein the method is performed *in vitro*.

Claim 3 (Cancelled)

Claim 4 (Previously Presented): The method of claim 1, wherein the vascular cells are smooth muscle cells.

Claim 5 (Previously Presented): The method of claim 2, wherein the vascular cells are smooth muscle cells.

Claim 6 (Previously Presented): The method of claim 1, wherein the vascular cells are endothelial cells.

Claim 7 (Previously Presented): The method of claim 2, wherein the vascular cells are endothelial cells.

Claim 8 (Previously Presented): The method of claim 1, wherein the cells are neoplasia cells.

Claim 9 (Previously Presented): The method of claim 2, wherein the cells are neoplasia cells.